84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer

Background

Therapy with Immune Checkpoint Inhibitors (ICI) is standard of care for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC). Still there are conflicting data about efficacy and safety, in regard to immune-related adverse event (irAEs) in the elderly patients. The aim of this study is to analyze efficacy and safety in the elderly patients with NSCLC undergoing treatment with ICI.

Methods

286 patients with NSCLC treated with at least one cycle of ICI have been included in the analysis. Clinical data were analyzed using binomial regression, and Chi-squared test.

Results

irAEs occurred in 63 out of 286 patients: gastrointestinal 14 (4.9%), endocrine 8 (2.8%), dermatologic 11 (3.8%), neurologic 6 (2.1%), cardiac 2 (0.7%), pulmonary 21 (7.3%), renal 1 (0.3%) and hepatic 5 (1.7%). According to CTCAE v5, 6 (9.5%) were Grade 1, 24 (38.1%) Grade 2, 30 (47.6%) Grade 3 and 3 (4.8%) Grade 4. Incidence of immune related adverse was not related to the age (p=0.3982). The probability of irAEs was correlated with the CIRS-G score (Cumulative Illness Rating Scale for Geriatrics) (p=0.00947). Between the different age-groups there was no difference in outcomes at 3-months (p=0.129) and 6-months (p=0.775) between the age groups.

Conclusions

Our analysis showed that patients older than 75 years didn’t experienced more toxicities. We observed a higher probability to experience irAES with higher CIRS-G score. This result underlines the importance to assess the comorbidities and the functional status of older patients with a geriatric assessment prior to oncological treatment. We could not find a difference in the outcomes at 3-months and 6-months between the age groups suggesting no significant difference in the efficacy of the immunotherapy. In conclusion, our analysis suggests that treatments with ICI’s is feasible and safe in older patients with NSCLC.

Legal entity responsible for the study

The authors.

Funding

HFR Fribourg.

Disclosure

V. Dougoud-Chauvin: Financial Interests, Personal, Advisory Board: Exact sciences. A. Curioni-Fontecedro: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Meyer Squibb, Boehringer Ingelheim, MSD, Novartis, Amgen, Roche, Takeda, Janssen; Financial Interests, Institutional, Advisory Board: Daiichi Sankyo; Non-Financial Interests, Personal, Leadership Role: Swiss Academy for Clinical Cancer Research (SAKK); Non-Financial Interests, Personal, Principal Investigator, of clinical trials: Roche; Non-Financial Interests, Personal, Principal Investigator, Clinical Trials: Takeda, MSD, Bristol Myers Squibb, Amgen, AstraZeneca; Non-Financial Interests, Personal, Principal Investigator, Clinical trials: iTEOS Therapeutics. All other authors have declared no conflicts of interest.